NCT01945359View on ClinicalTrials.gov

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions
Relapsing Remitting Multiple Sclerosis
Trial Locations (1)

84103

Rocky Mountain MS Research Group, Salt Lake City

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Rocky Mountain MS Research Group, LLC

OTHER

NCT01945359 - Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design | Biotech Hunter | Biotech Hunter